Leerink Partnrs Predicts Weaker Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for Exact Sciences in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.14 per share for the quarter, down from their prior forecast of $0.22. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.87) per share.

EXAS has been the subject of a number of other research reports. Sanford C. Bernstein increased their price objective on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Citigroup cut their price objective on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday. TD Cowen cut their price objective on Exact Sciences from $90.00 to $82.00 and set a “buy” rating for the company in a research report on Wednesday. Wells Fargo & Company assumed coverage on Exact Sciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 price objective for the company. Finally, Evercore ISI cut their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.06.

Exact Sciences Stock Performance

EXAS opened at $54.72 on Thursday. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62. The business has a 50 day moving average price of $67.14 and a two-hundred day moving average price of $56.65. The company has a market capitalization of $10.11 billion, a price-to-earnings ratio of -57.00 and a beta of 1.27. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year.

Hedge Funds Weigh In On Exact Sciences

A number of hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. increased its position in Exact Sciences by 67.5% during the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after buying an additional 11,800 shares during the last quarter. Sheaff Brock Investment Advisors LLC acquired a new position in Exact Sciences during the third quarter worth $225,000. CIBC Asset Management Inc increased its position in Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after buying an additional 371 shares during the last quarter. Black Swift Group LLC acquired a new position in Exact Sciences during the third quarter worth $204,000. Finally, Metis Global Partners LLC acquired a new position in Exact Sciences during the third quarter worth $241,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Exact Sciences

In other news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.36% of the stock is currently owned by company insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.